Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 7;40:188. doi: 10.1186/s13046-021-01996-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — The expression of GPD1 was downregulated in ccRCC tissues and inhibited the progression of ccRCC in vitro and in vivo. (A) Immunostainings of GPD1 protein in ccRCC tissues and paired normal kidney tissues. (B) Immunostainings of GPD1 protein in 69 ccRCC samples of TMA. (C) Kaplan-Meier curves for overall survival between the GPD1 high-expression group and the GPD1 low-expression group based on GPD1 IHC scores (8–12, GPD1 high-expression, n = 23 vs. 0–6, GPD1 low-expression, n = 46). (D-E) Cell proliferation as determined by CCK-8 and colony formation assays. (F-G) Cell migration and invasion as determined by wound healing and Transwell assays. Red lines denote the margins of the wound. (H) Cell apoptosis analysis of Caki1 and 769P cells overexpressing GPD1 or a negative control. (I) Cell cycle analysis of Caki1 and 769P cells overexpressing GPD1 or a negative control. The results are presented as the mean + SD of three independent experiments. (J) Images of tumors from the subcutaneous xenograft models implanted using Caki1 and 769P cells that stably overexpressed GPD1 or a negative control. The growth curves of tumors are shown (*p < 0.05, **p < 0.01). Abbreviations: GPD1, glycerol-3-phosphate dehydrogenase 1; ccRCC, clear cell renal cell carcinoma; TMA, tissue microarray; IHC, immunohistochemistry; TCGA, the cancer genome atlas; CCK-8, cell counting kit